YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Image source: The Motley Fool. DATE Wednesday, Aug. 12, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Senior Director of Corporate Operations - Jaclyn Jaffe Co-Founder, President and Chief Executive Officer - Claude Maraoui Chief Financial Office…
Journey Medical Corporation Q2 2026 Earnings Call Summary - Moby Strategic Performance Drivers Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. T…
Merck KGaA (MKKGY) shares rallied 5.3% in the last trading session to close at $33.55. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 5.9%…
SCOTTSDALE, Ariz., May 19, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company focused on developing, selling and marketing FDA-ap…
Journey Medical Corporation Q1 2026 Earnings Call Summary - Moby Strategic Performance Drivers Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. T…
Earnings Call Insights: Journey Medical (DERM) Q1 2026 MANAGEMENT VIEW * "We made solid progress in the first quarter of 2026, marking a strong start to what we believe will be a breakout year for Emrosi and Journey Medical." (Founder, Pre…
Image source: The Motley Fool. DATE May 13, 2026 CALL PARTICIPANTS Co-Founder, President and Chief Executive Officer — Claude Maraoui Chief Financial Officer — Joseph Benesch Chief Operating Officer and General Counsel — Ramsey Alloush Vic…
Journey Medical (NASDAQ:DERM) reported first-quarter financial results on Wednesday. The transcript from the company's first-quarter earnings call has been provided below. Benzinga APIs provide real-time access to earnings call transcripts…
* Journey Medical press release [https://seekingalpha.com/pr/20514250-journey-medical-corporation-reports-first-quarter-2026-financial-results-and-recent-corporate] (DERM [https://seekingalpha.com/symbol/DERM]): Q1 Non-GAAP EPS of $0.02. *…
Companies Reporting Before The Bell • Similarweb (NYSE:SMWB) is estimated to report quarterly earnings at $0.01 per share on revenue of $72.97 million. • Dominari Holdings (NASDAQ:DOMH) is projected to report earnings for its first quarter…
SCOTTSDALE, Ariz., May 06, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on developing, selling and marketing U.S. Food…
SAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Journey Medical Corporation (NASDAQ: DERM). The investigation focuses on Journey Medical’s executive officers an…
Journey Medical Corporation Q4 2025 Earnings Call Summary - Moby Strategic Execution and Commercial Momentum Achieved positive adjusted EBITDA for full-year 2025 and positive GAAP EBITDA in Q4, driven by the successful commercial launch of…
Earnings Call Insights: Journey Medical Corporation (DERM) Q4 2025 MANAGEMENT VIEW * Claude Maraoui, Founder, President, CEO & Director, described 2025 as a milestone year, highlighting the successful launch of Emrosi, Journey’s internally…
Journey Medical logo Key Points EMROSI generated $14.7 million in net sales during the three quarters it was available in 2025, recording about 53,000 prescriptions, more than 3,500 unique prescribers and a 1.4 refills-per-new-prescription…
SCOTTSDALE, Ariz., March 18, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug…
Journey Medical Corp (NASDAQ:DERM) is one of the best performing micro cap stocks in 2025. On January 4, Lake Street analyst Thomas Flaten reaffirmed a Buy rating on Journey Medical Corp (NASDAQ:DERM) with a $13 price target.Journey Medica…
Summers Value Partners, an investment management company, released its third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The Summers Value Fund LP returned a net return of 20.4% net in Q3 2025, surpassing the…
Third quarter 2025 net revenues were$17.6million Emrosi™ total prescriptions increased 146% over the second quarter of 2025 Emrosi net revenues were $4.9 million Company to hold conference call today at 4:30 p.m. ET to discuss the financia…
electroCore, Inc. (ECOR) came out with a quarterly loss of $0.4 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to a loss of $0.31 per share a year ago. These figures are adjusted for non-recurring items. Th…
SCOTTSDALE, Ariz., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug A…
FDA-approved Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) is available in the United States for the treatment of inflammatory lesions of rosacea in adults DFD-29 dem…
SCOTTSDALE, Ariz., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug A…
NEW YORK, Oct. 01, 2025 (GLOBE NEWSWIRE) -- via IBN -- ROTH Capital Partners, LLC (“ROTH”), www.roth.com, is pleased to announce it will host the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025, at the Metropolitan C…
Summers Value Partners, an investment management company, released its second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The Summers Value Fund LP returned a net return of -1.8% net in Q2 2025, trailing the…
(RTTNews) - Patience is a virtue - important in all aspects of life, and especially crucial when it comes to investing. As trading expert Steve Burns once said, "Much of our trading comes down to a battle between our patience and our impul…
Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today: Journey Medical DERM is a commercial-stage pharmaceutical company which focuses on the development and commercialization of pharmaceutical products for the treatmen…
SCOTTSDALE, Ariz., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug…
MIAMI, Aug. 20, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 85th Emerging Growth Conference on August 20 & 21, 2025. The Emerging Growth Conference identifies compa…
MIAMI, Aug. 19, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 85th Emerging Growth Conference on August 20 & 21, 2025. The Emerging Growth Conference identifies compa…
SCOTTSDALE, Ariz., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company primarily focused on selling and marketing FDA-app…
As the US market prepares to open on Wednesday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. [premarket] TODAY'S PRE-MARKET GAINERS TICKER CHANGE COMMENT BSLK…
Earnings Call Insights: Journey Medical Corporation (DERM) Q2 2025 MANAGEMENT VIEW * Claude Maraoui, CEO, highlighted the first full quarter of EMROSI's market launch, reporting "second quarter net product revenue of $15 million included a…
Second quarter 2025 revenues were$15.0million Emrosi™ net sales of $2.8 million generated in first full quarter on the market The Company joined the Russell 2000® and Russell 3000® Indexes in June 2025 Company to hold conference call today…
As we near the end of the ongoing earnings season, the scorecard for the Medical sector appears pretty decent. The sector primarily comprises pharma/biotech and medical device companies. Almost all the large biotech companies have already…
SCOTTSDALE, Ariz., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”, “we”, or “our”), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing…